Recruiting
Phase 2

SLIMM

Sponsor:

Srinvasan Beddhu

Code:

NCT05173714

Conditions

Chronic Kidney Diseases

Obesity

Eligibility Criteria

Sex: All

Age: 20+

Healthy Volunteers: Not accepted

Interventions

SLIMM

Standard Resistance Training

Guided Resistance Training

Placebo

Semaglutide

Study Details

Brief summary:

  • Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death.
  • In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained.
  • Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2.
  • This NIH funded study is conducted at the University of Utah and Stanford University.
  • The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Conditions

Chronic Kidney Diseases

Obesity

Study ID

NCT05173714

Start date

Dec 1, 2021

Status verified date

Jul, 2026

Completion date

Mar 31, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 20+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to <60 mL/min/1.73m\^2
  • Able to perform resistance training
  • Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Exclusion Criteria:

  • Type 1 Diabetes
  • History of gastroparesis or paralytic ileus
  • At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
  • Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
  • Previous bariatric surgery
  • Medical condition likely to limit survival to less than 1 year
  • Anticipated start of dialysis or kidney transplantation within 6 months
  • Any factors judged by the investigator or study team to likely limit adherence to interventions
  • Vulnerable populations- pregnant or incarcerated
  • Enrolled in interventional trials using drugs or devices
  • Not able to undergo informed consent
  • Recent hospitalizations or major interventional procedures done within the past 60 days
  • Known or suspected hypersensitivity to tegaderm
  • Use of any GLP-1 receptor agonist within 30 days prior to screening
  • Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
  • Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
  • Presence of metastatic cancer
  • Current use of mobility aid(s)
  • Living in the same household of a participant already enrolled in the study

Study Design

Enrollment

156 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: SLIMM + Standard RT + Placebo

SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo

active comparator: SLIMM + Guided RT + Placebo

SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo

experimental: SLIMM + Guided RT + Semaglutide

SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide

Interventions

SLIMM

Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.

Standard Resistance Training

Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.

Guided Resistance Training

Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.

Placebo

Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.

Semaglutide

Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.

Primary outcome measure

  • Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization [ Time Frame: Randomization to 12 Months ]

Central Contacts and Locations

Central contacts

Amara Sarwal, M.D.

801-585-9815Amara.Sarwal@hsc.utah.edu

Locations

Stanford University

Recruiting

Stanford, California, United States, 94305

Contacts

Edison Lee

650-497-7526elee125@stanford.edu

Principal Investigator:

Glenn M Chertow, M.D.

University of Utah

Recruiting

Salt Lake City, Utah, United States, 84108

Contacts

Judy Carle

801-585-1113jcarle@hsc.utah.edu

Principal Investigator:

Srinivasan Beddhu, M.D.

More Information

Sponsor

Srinvasan Beddhu

Last update posted

Jul 27, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Srinvasan Beddhu on 2026-07-27.